100.19
-1.45 (-1.43%)
| Previous Close | 101.64 |
| Open | 101.60 |
| Volume | 111,685 |
| Avg. Volume (3M) | 121,475 |
| Market Cap | 1,933,085,952 |
| Price / Earnings (Forward) | 19.08 |
| Price / Sales | 11.69 |
| Price / Book | 2.76 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Profit Margin | -73.07% |
| Operating Margin (TTM) | -80.87% |
| Diluted EPS (TTM) | -7.29 |
| Quarterly Revenue Growth (YOY) | 46.30% |
| Total Debt/Equity (MRQ) | 0.56% |
| Current Ratio (MRQ) | 5.27 |
| Operating Cash Flow (TTM) | 52.87 M |
| Levered Free Cash Flow (TTM) | 63.35 M |
| Return on Assets (TTM) | -1.14% |
| Return on Equity (TTM) | -16.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Ligand Pharmaceuticals Incorpor | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | 4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 2.00 |
|
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.29% |
| % Held by Institutions | 99.82% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 145.00 (Oppenheimer, 44.73%) | Buy |
| Median | 144.00 (43.73%) | |
| Low | 143.00 (Stifel, 42.73%) | Buy |
| Average | 144.00 (43.73%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 102.89 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Oppenheimer | 09 May 2025 | 145.00 (44.73%) | Buy | 104.48 |
| Stifel | 10 Apr 2025 | 143.00 (42.73%) | Buy | 101.29 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| REARDON ANDREW | - | 114.98 | -500 | -57,490 |
| Aggregate Net Quantity | -500 | |||
| Aggregate Net Value ($) | -57,490 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 114.98 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| REARDON ANDREW | Officer | 23 Jun 2025 | Sell (-) | 500 | 114.98 | 57,490 |
| Date | Type | Details |
|---|---|---|
| 02 Jul 2025 | Announcement | Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics |
| 11 Jun 2025 | Announcement | Ligand Announces 2025 Investor Day in New York City |
| 14 May 2025 | Announcement | Ligand to Ring the Nasdaq Opening Bell on May 19, 2025 |
| 08 May 2025 | Announcement | Ligand Reports First Quarter 2025 Financial Results |
| 01 May 2025 | Announcement | Ligand to Participate in May Investor Conferences |
| 24 Apr 2025 | Announcement | Ligand to Report First Quarter 2025 Financial Results on May 8, 2025 |
| 17 Apr 2025 | Announcement | Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |